Core Viewpoint - The inclusion of Lairosilib (GB491) in the National Medical Insurance Drug List is expected to enhance patient accessibility and accelerate commercialization, thereby boosting innovative returns [1] Group 1: Drug Inclusion - Lairosilib (GB491) has been included in the National Medical Insurance Drug List published by the National Healthcare Security Administration on December 7, 2025 [1] - This marks the first time Lairosilib (GB491) has been included in the national medical insurance drug list [1] - The new drug list will take effect on January 1, 2026 [1] Group 2: Drug Profile - Lairosilib (GB491) is a novel, highly selective oral CDK4/6 inhibitor indicated for adult patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer [1] - It is used in combination with aromatase inhibitors as initial endocrine therapy and with Fulvestrant for patients with disease progression after prior endocrine therapy [1] Group 3: Market Impact - The company believes that the inclusion of Lairosilib (GB491) in the insurance list will significantly improve patient access to the drug and reduce their financial burden [1] - This development is expected to accelerate the commercialization process and market penetration of Lairosilib (GB491) [1] - The move is anticipated to further enhance innovative returns for the company [1]
嘉和生物-B：来罗西利(GB491)纳入国家医保药品目录